|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
01833 PA GOODDOCTOR
Nominal 
14.440 -0.200 (-1.366%) | 2023/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | 2020/12 RMB(K¥) | 2019/12 RMB(K¥) | |
| Turnover | 4,673,562 | -24.682% | 6,205,082 | 7,334,214 | 6,865,987 | 5,065,429 |
| Cost of Sales | (3,165,049) | -30.191% | (4,533,851) | (5,627,353) | (5,001,573) | (3,894,000) |
| Gross Profit | 1,508,513 | -9.736% | 1,671,231 | 1,706,861 | 1,864,414 | 1,171,429 |
| 2023/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | 2020/12 RMB(K¥) | 2019/12 RMB(K¥) | ||
| Change in FV & Impairment on Inv. Prop. | -- | -- | -- | -- | -- | -- | |
| Change in FV & Impairment on Others | -- | -- | -- | -- | -- | -- | |
| Profit / (Loss) on Disposal | -- | -- | -- | -- | -- | -- | |
| Other Non-operating Items | -- | -- | -- | -- | -- | -- | |
| Share of Results of Asso. & JCEs | 251 | -- | (66,323) | (38,773) | (121,895) | (27,429) | |
| Profit / (Loss) before Taxation | (331,893) | -47.831% | (636,183) | (1,523,607) | (941,348) | (734,129) | |
| Taxation | (2,965) | -13.050% | (3,410) | (15,792) | (7,155) | (12,587) | |
| Profit / (Loss) from Discontinued Operations | -- | -- | -- | -- | -- | -- | |
| Non-controlling Interests | 12,264 | 246.931% | 3,535 | 1,216 | 25 | 12,856 | |
| Others | -- | -- | -- | -- | -- | -- | |
| Profit / (Loss) Attributable to Shareholders | (322,594) | -49.282% | (636,058) | (1,538,183) | (948,478) | (733,860) | |
| 2023/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | 2020/12 RMB(K¥) | 2019/12 RMB(K¥) | |
| Net Finance Costs / (Income) | (255,193) | -1.065% | (257,939) | (299,631) | (199,160) | (252,689) |
| Depreciation & Amortisation | 160,779 | -15.459% | 190,178 | 206,940 | 169,777 | 145,708 |
| Directors' Emoluments | 30,295 | 13.007% | 26,808 | 28,309 | 14,307 | 20,941 |
| 2023/12 - Final | %Chg (Compare to Final) | 2022/12 | 2021/12 | 2020/12 | 2019/12 | |
| Auditor's Opinion Status | Unqualified | -- | Unqualified | Unqualified | Unqualified | Unqualified |
Market Valuation Indicators
| 2023/12 - Final | %Chg (Compare to Final) | 2022/12 | 2021/12 | 2020/12 | 2019/12 | |
| EPS (cts) | -30.000 | -49.153% | -59.000 | -139.000 | -92.000 | -73.000 |
| DPS (cts) | 0.000 | -- | 0.000 | 0.000 | 0.000 | 0.000 |
| Dividend Payout Ratio (%) | -- | -- | -- | -- | -- | -- |
| Cash flow per share ($) | (0.262) | -- | (0.750) | (1.272) | (1.071) | (0.504) |
| NBV per share ($) | 11.873 | -- | 12.095 | 12.275 | 13.800 | 9.040 |
| Remarks: | Real time quote last updated: 21/11/2024 18:00 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service. | |
| Profit / (Loss) Attributable to Shareholders (K¥) | RMB 56,648 |
| %Change | -- |
| EPS / (LPS) | RMB 0.050 |
| NBV Per Share (¥) | RMB 11.958 |